JPH10500125A - IFN−β液体製剤 - Google Patents
IFN−β液体製剤Info
- Publication number
- JPH10500125A JPH10500125A JP7529360A JP52936095A JPH10500125A JP H10500125 A JPH10500125 A JP H10500125A JP 7529360 A JP7529360 A JP 7529360A JP 52936095 A JP52936095 A JP 52936095A JP H10500125 A JPH10500125 A JP H10500125A
- Authority
- JP
- Japan
- Prior art keywords
- liquid pharmaceutical
- interferon
- beta
- formulation
- buffer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000467 Interferon-beta Proteins 0.000 title claims abstract description 36
- 239000007788 liquid Substances 0.000 title claims description 34
- 102100026720 Interferon beta Human genes 0.000 title description 15
- 238000002360 preparation method Methods 0.000 title description 2
- 229960001388 interferon-beta Drugs 0.000 claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 25
- 238000009472 formulation Methods 0.000 claims abstract description 22
- 102000003996 Interferon-beta Human genes 0.000 claims abstract description 21
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 18
- 229930195725 Mannitol Natural products 0.000 claims abstract description 18
- 239000008351 acetate buffer Substances 0.000 claims abstract description 18
- 239000000872 buffer Substances 0.000 claims abstract description 18
- 239000000594 mannitol Substances 0.000 claims abstract description 18
- 235000010355 mannitol Nutrition 0.000 claims abstract description 18
- 102000008100 Human Serum Albumin Human genes 0.000 claims abstract description 15
- 108091006905 Human Serum Albumin Proteins 0.000 claims abstract description 15
- 239000012669 liquid formulation Substances 0.000 claims abstract description 8
- 229920005862 polyol Polymers 0.000 claims abstract description 8
- 150000003077 polyols Chemical class 0.000 claims abstract description 8
- 150000001413 amino acids Chemical class 0.000 claims abstract description 6
- 235000000346 sugar Nutrition 0.000 claims abstract description 6
- 239000000243 solution Substances 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 14
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000003381 stabilizer Substances 0.000 claims description 9
- 102000009027 Albumins Human genes 0.000 claims description 8
- 108010088751 Albumins Proteins 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 6
- 238000007865 diluting Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 238000003860 storage Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 150000008163 sugars Chemical class 0.000 claims 1
- 230000000694 effects Effects 0.000 description 13
- 102000014150 Interferons Human genes 0.000 description 8
- 108010050904 Interferons Proteins 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 235000013681 dietary sucrose Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 229960004793 sucrose Drugs 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000008364 bulk solution Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 229940047124 interferons Drugs 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101001054334 Homo sapiens Interferon beta Proteins 0.000 description 1
- 229910019065 NaOH 1 M Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000008362 succinate buffer Substances 0.000 description 1
- 239000011123 type I (borosilicate glass) Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.インターフェロン−ベータおよび安定剤としてのポリオール、非還元糖又 はアミノ酸を含んでなる液体医薬製剤。 2.安定剤が、マンニトール、サーカロースおよびグリシンから選ばれる、請 求の範囲第1項記載の液体医薬製剤。 3.安定剤がマンニトールである、請求の範囲第2項記載の液体医薬製剤。 4.インターフェロン−ベータが組換え体である、請求の範囲第1〜3項のい ずれか1項に記載の液体医薬製剤。 5.インターフェロン−ベータが、0.6〜1 MIU/mlの量で存在する請求の範 囲第1〜4項のいずれか1項に記載の液体医薬製剤。 6.3.0〜4.0 の値に液体製剤のpHを維持することのできる緩衝液を、更に含 んでなる、請求の範囲第1〜5項のいずれか1項に記載の液体医薬製剤。 7.緩衝液がアセタート緩衝液である、請求の範囲第6項記載の液体医薬製剤 。 8.緩衝液が0.01Mの濃度を有する、請求の範囲第6又は7項記載の液体医薬 製剤。 9.ヒトアルブミンをさらに含んでなる、請求の範囲第1〜8項のいずれか1 項に記載の液体医薬製剤。 10.pH3.5 の0.01Mアセタート緩衝液中に1 MIU/mlのインターフェロン−ベ ータ、54.6mg/mlのマンニトール、0.5mg/mlのアルブミンを含んでなる、請求 の範囲第1〜9項のいずれか1項に記載の液体医薬製剤。 11.賦形剤の溶液を用いてインターフェロン−ベータを希釈することを含んで なる、請求の範囲第1〜10項のいずれか1項に記載の 液体医薬製剤の製造方法。 12.使用前の貯蔵に対し適切な容器中で無菌条件下密封されている、請求の範 囲第1〜10項のいずれか1項に記載の液体医薬製剤の提示形態。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT94A000300 | 1994-05-16 | ||
ITRM940300A IT1272252B (it) | 1994-05-16 | 1994-05-16 | Formulazioni liquide di interferone beta |
PCT/EP1995/001825 WO1995031213A1 (en) | 1994-05-16 | 1995-05-15 | IFN-β LIQUID FORMULATIONS |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10500125A true JPH10500125A (ja) | 1998-01-06 |
JP3701675B2 JP3701675B2 (ja) | 2005-10-05 |
Family
ID=11402534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52936095A Expired - Lifetime JP3701675B2 (ja) | 1994-05-16 | 1995-05-15 | IFN−β液体製剤 |
Country Status (13)
Country | Link |
---|---|
US (2) | US6852314B1 (ja) |
EP (1) | EP0759775B1 (ja) |
JP (1) | JP3701675B2 (ja) |
AT (1) | ATE194917T1 (ja) |
AU (1) | AU704827B2 (ja) |
CA (1) | CA2190465A1 (ja) |
DE (1) | DE69518152T2 (ja) |
DK (1) | DK0759775T3 (ja) |
ES (1) | ES2148526T3 (ja) |
GR (1) | GR3034309T3 (ja) |
IT (1) | IT1272252B (ja) |
PT (1) | PT759775E (ja) |
WO (1) | WO1995031213A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004529917A (ja) * | 2001-04-09 | 2004-09-30 | カイロン コーポレイション | インターフェロン−βのHSA非含有処方物 |
JP2004538275A (ja) * | 2001-07-09 | 2004-12-24 | シエーリング アクチエンゲゼルシャフト | ヒトインターフェロン−β配合物 |
JP2006525280A (ja) * | 2003-05-01 | 2006-11-09 | アレス トレーディング ソシエテ アノニム | Hsaを含まない安定なインターフェロン液体製剤 |
JP2013543872A (ja) * | 2010-11-22 | 2013-12-09 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | インターフェロン−βの安定に保存される組成物 |
WO2017170626A1 (ja) * | 2016-03-30 | 2017-10-05 | 千寿製薬株式会社 | 水性液剤 |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5952300A (en) * | 1996-04-19 | 1999-09-14 | Merck & Co., Inc. | Antifungal compositions |
US20030190307A1 (en) | 1996-12-24 | 2003-10-09 | Biogen, Inc. | Stable liquid interferon formulations |
CN1222315C (zh) * | 1996-12-24 | 2005-10-12 | 拜奥根有限公司 | 稳定的液体干扰素制剂 |
EP1426058A3 (de) | 1997-09-23 | 2004-07-28 | Dr. Rentschler Biotechnologie GmbH | Flüssige Interferon-Beta Formulierungen |
KR19990075253A (ko) * | 1998-03-18 | 1999-10-15 | 성재갑 | 약학적으로 안정한 인터페론 제 |
AU3473999A (en) * | 1998-04-03 | 1999-10-25 | Chiron Corporation | Injectable igf-formulations containing succinate as buffering agent |
AU3070702A (en) | 2000-11-07 | 2002-05-21 | Chiron Corp | Stabilized inteferon compositions |
EP1748788A1 (en) | 2004-05-17 | 2007-02-07 | Ares Trading S.A. | Hydrogel interferon formulations |
MXPA06014078A (es) | 2004-06-01 | 2007-02-15 | Ares Trading Sa | Formulaciones liquidas estabilizadas de interferon. |
US7913435B1 (en) * | 2005-09-28 | 2011-03-29 | Hummel Iii John F | Vehicle display bracket system |
PL2234645T3 (pl) * | 2007-12-20 | 2012-10-31 | Merck Serono Sa | Preparaty interferonu-beta modyfikowanego PEG |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5821691A (ja) * | 1981-07-29 | 1983-02-08 | Mochida Pharmaceut Co Ltd | α−及びβ−インタ−フェロンの精製方法 |
EP0080879B1 (en) * | 1981-11-28 | 1986-10-01 | Sunstar Kabushiki Kaisha | Pharmaceutical composition containing interferon in stable state |
AU1234383A (en) | 1982-03-17 | 1983-09-22 | Inter-Yeda Ltd. | Interferon stabilised with polyvinyl-pyrrolidone |
US5643566A (en) * | 1982-09-23 | 1997-07-01 | Cetus Corporation | Formulation processes for lipophilic proteins |
US4724232A (en) * | 1985-03-16 | 1988-02-09 | Burroughs Wellcome Co. | Treatment of human viral infections |
US5183746A (en) * | 1986-10-27 | 1993-02-02 | Schering Aktiengesellschaft | Formulation processes for pharmaceutical compositions of recombinant β- |
CA1294215C (en) | 1986-10-27 | 1992-01-14 | Ze'ev Shaked | Pharmaceutical compositions of recombinant beta-interferon and formulation processes |
IL88233A (en) | 1987-11-03 | 1993-08-18 | Genentech Inc | Gamma interferon formulation |
US5004605A (en) * | 1987-12-10 | 1991-04-02 | Cetus Corporation | Low pH pharmaceutical compositions of recombinant β-interferon |
-
1994
- 1994-05-16 IT ITRM940300A patent/IT1272252B/it active IP Right Grant
-
1995
- 1995-05-15 AT AT95921749T patent/ATE194917T1/de active
- 1995-05-15 EP EP95921749A patent/EP0759775B1/en not_active Expired - Lifetime
- 1995-05-15 JP JP52936095A patent/JP3701675B2/ja not_active Expired - Lifetime
- 1995-05-15 PT PT95921749T patent/PT759775E/pt unknown
- 1995-05-15 DK DK95921749T patent/DK0759775T3/da active
- 1995-05-15 DE DE69518152T patent/DE69518152T2/de not_active Expired - Lifetime
- 1995-05-15 WO PCT/EP1995/001825 patent/WO1995031213A1/en active IP Right Grant
- 1995-05-15 CA CA002190465A patent/CA2190465A1/en not_active Withdrawn
- 1995-05-15 ES ES95921749T patent/ES2148526T3/es not_active Expired - Lifetime
- 1995-05-15 AU AU26704/95A patent/AU704827B2/en not_active Expired
- 1995-05-15 US US08/737,633 patent/US6852314B1/en not_active Expired - Lifetime
-
2000
- 2000-08-31 GR GR20000401996T patent/GR3034309T3/el unknown
-
2004
- 2004-07-16 US US10/892,181 patent/US7407651B2/en not_active Expired - Fee Related
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004529917A (ja) * | 2001-04-09 | 2004-09-30 | カイロン コーポレイション | インターフェロン−βのHSA非含有処方物 |
JP2013064020A (ja) * | 2001-04-09 | 2013-04-11 | Novartis Vaccines & Diagnostics Inc | インターフェロン−βのHSA非含有処方物 |
JP2015044882A (ja) * | 2001-04-09 | 2015-03-12 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | インターフェロン−βのHSA非含有処方物 |
JP2004538275A (ja) * | 2001-07-09 | 2004-12-24 | シエーリング アクチエンゲゼルシャフト | ヒトインターフェロン−β配合物 |
JP2006525280A (ja) * | 2003-05-01 | 2006-11-09 | アレス トレーディング ソシエテ アノニム | Hsaを含まない安定なインターフェロン液体製剤 |
JP2013543872A (ja) * | 2010-11-22 | 2013-12-09 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | インターフェロン−βの安定に保存される組成物 |
WO2017170626A1 (ja) * | 2016-03-30 | 2017-10-05 | 千寿製薬株式会社 | 水性液剤 |
Also Published As
Publication number | Publication date |
---|---|
ITRM940300A0 (it) | 1994-05-16 |
PT759775E (pt) | 2000-11-30 |
JP3701675B2 (ja) | 2005-10-05 |
ITRM940300A1 (it) | 1995-11-16 |
AU704827B2 (en) | 1999-05-06 |
DE69518152T2 (de) | 2000-12-14 |
DE69518152D1 (de) | 2000-08-31 |
GR3034309T3 (en) | 2000-12-29 |
US6852314B1 (en) | 2005-02-08 |
ES2148526T3 (es) | 2000-10-16 |
CA2190465A1 (en) | 1995-11-23 |
DK0759775T3 (da) | 2000-11-13 |
EP0759775A1 (en) | 1997-03-05 |
EP0759775B1 (en) | 2000-07-26 |
IT1272252B (it) | 1997-06-16 |
WO1995031213A1 (en) | 1995-11-23 |
ATE194917T1 (de) | 2000-08-15 |
US7407651B2 (en) | 2008-08-05 |
US20040265270A1 (en) | 2004-12-30 |
AU2670495A (en) | 1995-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3701675B2 (ja) | IFN−β液体製剤 | |
KR100401401B1 (ko) | 안정한알파인터페론수용액제형 | |
EP0955062B1 (en) | Human growth hormone aqueous formulation | |
AU666007B2 (en) | Protein formulation comprising growth hormone | |
US4847079A (en) | Biologically stable interferon compositions comprising thimerosal | |
US6448225B2 (en) | Human growth hormone aqueous formulation | |
US5763394A (en) | Human growth hormone aqueous formulation | |
EP0374257B1 (en) | STABLE INTERFERON $g(b) COMPOSITION | |
US20050163752A1 (en) | Human interferon-beta formulations | |
CN113398250B (zh) | 液体***药物制剂及用途 | |
Ruiz et al. | Long-term stabilization of recombinant human interferon α 2b in aqueous solution without serum albumin | |
IL139320A (en) | Pharmaceutical preparations containing human parathyroid hormone | |
AU4065393A (en) | Pharmaceutical compositions containing IL-6 | |
JP3291340B2 (ja) | 非グリコシル化還元型組換えヒトil2の安定化医薬組成物及びその製造方法 | |
WO1999062542A1 (en) | Recombinant human interferon beta-1a (ifn-beta-1a) formulation | |
MXPA03008546A (es) | Formulaciones liquidas de ifn-beta. | |
Kim et al. | Stabilization of glycoprotein liquid formulation using arginine: A study with lactoferrin as a model protein | |
CA1295240C (en) | Biologically stable interferon compositions | |
CN112933039A (zh) | 一种重组人***液体制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040907 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20041207 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050303 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050614 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050714 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080722 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080722 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080722 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080722 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090722 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090722 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100722 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100722 Year of fee payment: 5 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100722 Year of fee payment: 5 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110722 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110722 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120722 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120722 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130722 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |